Today, Eurofins Discovery, a major supplier of goods and services for drug discovery research and a member of the Eurofins (Paris:ERF) network of laboratories, announced the launch of Discovery.AI SAFIRE: A collection of ADMET forecasts for in-silico refinement and assessment. SAFIRE is a sophisticated platform that uses machine learning (ML), artificial intelligence (AI), and proprietary datasets to provide a special aptitude for accelerating discoveries. Customers can now access SAFIRE via the Eurofins Discovery website.
The seasoned informatics specialists at Eurofins Discovery have gathered enormous, excellent, and varied datasets that offer a special method for forecasting the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) characteristics of compounds. It raises the bar for predictive analytics.
SAFIRE makes use of information from the world-class BioPrint database maintained by Eurofins Discovery after years of painstaking investigation and data collection. As evidenced by a recent paper published in the Future Medical Chemistry journal, the outcome is a more potent research instrument that excels beyond the constraints of existing predictive systems presently available on the market.
End-users were the focus of SAFIRE’s design, which includes a full suite of predictive ADME models and scoring tools to support decision-making. It has the ability to expedite drug discovery initiatives from the point of initial hit discovery to lead optimisation.
In what ways does SAFIRE surpass the current market limitations of predictive systems? When trained with both public datasets utilised by the SAFIRE platform and proprietary data from the BioPrint database, Eurofins Discovery’s models can predict the ADMET properties of compounds with speed and efficiency, as evidenced by published findings of AI advancements. Through the achievement of Matthews Correlation Coefficient values larger than 0.4 and accuracy rates above 80%, this technique has demonstrated better model performance as well as enlarged the chemical space covered by the models.
About Eurofins: The world’s foremost authority on bioanalysis
Life is being tested by Eurofins. The companies that make up the Eurofins network of companies think that they are world leaders in contract research services for agroscience, advanced material sciences, forensics, food, environment, pharmaceutical, and cosmetic product testing. Additionally, it leads the industry in a number of genetic testing and laboratory services, supports clinical research, and develops and manufactures biopharmaceutical contracts. Additionally, it is becoming more and more prevalent in in-vitro diagnostic products and highly specialist molecular clinical diagnostic tests.
In addition to offering a portfolio of over 200,000 analytical methods to assess the safety, identity, composition, authenticity, origin, traceability, and purity of a wide range of products, Eurofins also offers cutting-edge clinical diagnostic testing services and in-vitro diagnostic products. With approximately 62,000 employees spread across a decentralised and entrepreneurial network of more than 900 laboratories in 62 countries.
The wide range of services provided by European businesses is crucial for both human and environmental health and safety. Our goal is to give our customers the best possible service, creative solutions, and accurate results in the quickest turnaround time (TAT) by continuing to invest in becoming entirely digital and maintaining the best network of cutting-edge laboratories and equipment. The businesses of Eurofins are in a good position to meet the rising expectations of regulatory bodies, the ever-changing needs of healthcare professionals worldwide, and their clients’ ever-tougher quality and safety standards.
Since its founding, Eurofins has experienced rapid growth, and the company’s goal is to keep broadening both its technological offering and its geographic scope. The Group provides its clients with distinctive analytical solutions by using the most recent advancements in analytical chemistry and biotechnology through research and development as well as acquisitions.
